

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

UPDATE ON VERY SUBSTANTIAL ACQUISITION

Reference is made to the circular of the Company dated 12 February 2018 (the “**Circular**”) in relation to the Proposed Acquisition. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Company hereby announces that it received the Letter of No Further Review (Shang Fan Long Chu Shen Han [2018] No. 133) (《不實施進一步審查決定書》) from the Anti-Monopoly Bureau of the Ministry of Commerce of the PRC (中國商務部反壟斷局). According to the said document, after preliminary examination by the Anti-Monopoly Bureau of the Ministry of Commerce of the PRC it decided that the Proposed Acquisition will not be subject to further review and the Company may proceed with the Proposed Acquisition from 9 April 2018.

The Board of

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 13 April 2018

As at the Announcement Date, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong and Mr. Wu Changhai as executive Directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive Directors.